|
Name |
4'-Hydroxycladosporin
|
Molecular Formula | C16H20O6 | |
IUPAC Name* |
(3R)-6,8-dihydroxy-3-[[(2R,4R,6S)-4-hydroxy-6-methyloxan-2-yl]methyl]-3,4-dihydroisochromen-1-one
|
|
SMILES |
C[C@H]1C[C@H](C[C@@H](O1)C[C@H]2CC3=C(C(=CC(=C3)O)O)C(=O)O2)O
|
|
InChI |
InChI=1S/C16H20O6/c1-8-2-10(17)5-13(21-8)7-12-4-9-3-11(18)6-14(19)15(9)16(20)22-12/h3,6,8,10,12-13,17-19H,2,4-5,7H2,1H3/t8-,10+,12+,13+/m0/s1
|
|
InChIKey |
BGBCTXXTDYWYHE-VVUYAAESSA-N
|
|
Synonyms |
4'-Hydroxyasperentin; 4'-Hydroxycladosporin; 2WMQ2799OP; 51484-09-4; UNII-2WMQ2799OP; CHEMBL3759813; Q27255708; 3,4-Dihydro-6,8-dihydroxy-3-(4-hydroxy-6-methyltetrahydropyran-2-ylmethyl)isocoumarin; (3R)-3,4-DIHYDRO-6,8-DIHYDROXY-3-(((2R,4R,6S)-TETRAHYDRO-4-HYDROXY-6-METHYL-2H-PYRAN-2-YL)METHYL)-1H-2-BENZOPYRAN-1-ONE; 1H-2-BENZOPYRAN-1-ONE, 3,4-DIHYDRO-6,8-DIHYDROXY-3-(((2R,4R,6S)-TETRAHYDRO-4-HYDROXY-6-METHYL-2H-PYRAN-2-YL)METHYL)-, (3R)-; 1H-2-Benzopyran-1-one, 3,4-dihydro-6,8-dihydroxy-3-((tetrahydro-4-hydroxy-6-methyl-2H-pyran-2-yl)methyl)-
|
|
CAS | 51484-09-4 | |
PubChem CID | 119057372 | |
ChEMBL ID | CHEMBL3759813 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 308.33 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.723 |
Caco-2 Permeability: | -5.428 | MDCK Permeability: | 0.00002770 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.975 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.018 |
30% Bioavailability (F30%): | 0.778 |
Blood-Brain-Barrier Penetration (BBB): | 0.459 | Plasma Protein Binding (PPB): | 60.10% |
Volume Distribution (VD): | 2.256 | Fu: | 30.93% |
CYP1A2-inhibitor: | 0.547 | CYP1A2-substrate: | 0.088 |
CYP2C19-inhibitor: | 0.075 | CYP2C19-substrate: | 0.152 |
CYP2C9-inhibitor: | 0.285 | CYP2C9-substrate: | 0.933 |
CYP2D6-inhibitor: | 0.174 | CYP2D6-substrate: | 0.209 |
CYP3A4-inhibitor: | 0.352 | CYP3A4-substrate: | 0.212 |
Clearance (CL): | 13.579 | Half-life (T1/2): | 0.761 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.841 |
Drug-inuced Liver Injury (DILI): | 0.943 | AMES Toxicity: | 0.453 |
Rat Oral Acute Toxicity: | 0.074 | Maximum Recommended Daily Dose: | 0.998 |
Skin Sensitization: | 0.936 | Carcinogencity: | 0.908 |
Eye Corrosion: | 0.023 | Eye Irritation: | 0.946 |
Respiratory Toxicity: | 0.861 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003043 | 0.718 | D07MGA | 0.298 | ||||
ENC002956 | 0.718 | D0AZ8C | 0.252 | ||||
ENC003280 | 0.714 | D0Z1FX | 0.237 | ||||
ENC002947 | 0.714 | D0WE3O | 0.235 | ||||
ENC002270 | 0.714 | D04JHN | 0.235 | ||||
ENC005476 | 0.557 | D02NSF | 0.230 | ||||
ENC002946 | 0.557 | D03YVO | 0.227 | ||||
ENC005248 | 0.547 | D06WTZ | 0.226 | ||||
ENC000960 | 0.547 | D0I9HF | 0.226 | ||||
ENC005249 | 0.547 | D0PG8O | 0.222 |